Key Highlights

  • Shares closed at $64.66 at last closing, up 4.39%.
  • Second-quarter 2026 Revenue rose about 22% to roughly $382.5 million, and the company raised its full-year guidance.
  • Growth was driven by its data-and-services Business and genomic testing.
  • Tempus AI remains unprofitable as it invests heavily in its AI-driven precision-medicine platform.

Tempus AI (NASDAQ:TEM) is a health-technology company that applies artificial intelligence and Data Analytics to precision medicine, generating and analyzing molecular and clinical data, particularly in oncology. Shares closed at $64.66 at last closing, up 4.39%.

Its business includes genomic testing and a large library of clinical and molecular data that it monetizes through data-and-services arrangements, so its results depend on test volumes, data-and-services revenue, and its ability to grow while investing heavily in its platform.

Latest Developments

In its second-quarter 2026 results, Tempus reported revenue rising about 22% to roughly $382.5 million and raised its full-year guidance, with management highlighting growth in its data-and-services business and pricing opportunities alongside its genomic testing. Investors should confirm the latest revenue and its growth by segment, gross margins, the net loss and its trajectory, and updated guidance directly from SEC filings.

Financial and Business Position

Tempus's Investment case rests on the growth of its genomic testing and its data-and-services business, the value of its large clinical and molecular data library, and its path toward profitability, offset by ongoing losses and the Capital it consumes. Investors should watch revenue growth by segment, gross margins, the net loss moving toward breakeven, and data-and-services growth.

Stock-Market Context

TEM shares closed at $64.66 at last closing, up 4.39%. The stock is a high-growth health-technology company whose shares are volatile and sensitive to revenue growth, Margin and loss trends, and sentiment toward AI and precision-medicine names.

What Investors Should Watch

Watch revenue growth by segment including genomics and data-and-services, gross margins, the net loss moving toward breakeven, cash and burn, and data-and-services growth and contract value. Sustained strong revenue growth combined with margin improvement and clear progress toward profitability would be the clearest signs of a positive surprise, while a growth slowdown or continued heavy losses would be the main risks.